Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
JournalAntimicrobial Agents and Chemotherapy
PublisherAmerican Society for Microbiology
MetadataShow full item record
AbstractOutbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.
Middle East Respiratory Syndrome Coronavirus
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84902176510&doi=10.1128%2fAAC.03036-14&partnerID=40&md5=c82f3f5e8c97b8be79573df306c340a6; http://hdl.handle.net/10713/12417
- Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
- Authors: de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ
- Issue date: 2014 Aug
- Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors.
- Authors: LaFemina RL
- Issue date: 2014 Aug
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
- Authors: Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB
- Issue date: 2016 Oct 1
- 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
- Authors: Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S, Groutas WC, Chang KO
- Issue date: 2020 Aug 19
- Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.
- Authors: Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB
- Issue date: 2020 Oct 14